Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

Plasma Aβ—First Sign of AD, But Tough to Measure Prospectively? | ALZFORUM,

The Alzheimer’s Clinical Trials Consortium’s AHEAD 3-45 trial of lecanemab has already begun to use C2N’s CLIA-approved mass spectrometry test for …, The Alzheimer’s Clinical Trials Consortium’s AHEAD 3-45 trial of lecanemab has already begun to use C2N’s CLIA-approved mass spectrometry test for …, Read More

Scroll to Top